Small intestine cancer diagnostic study of choice

Jump to navigation Jump to search

Small intestine cancer Microchapters

Home

Patient Information

Overview

Historical perspective

Classification

Pathophysiology

Causes

Differentiating Small intestine cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-Ray

CT Scan

MRI

Echocardiography and Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Small intestine cancer diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Small intestine cancer diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Small intestine cancer diagnostic study of choice

CDC on Small intestine cancer diagnostic study of choice

Small intestine cancer diagnostic study of choice in the news

Blogs on Small intestine cancer diagnostic study of choice

Directions to Hospitals Treating Small intestine cancer

Risk calculators and risk factors for Small intestine cancer diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Diagnostic Study of Choice

Study of choice

[Name of the investigation] is the gold standard test for the diagnosis of [disease name].

OR

The following result of [gold standard test] is confirmatory of [disease name]:

  • [Result 1]
  • [Result 2]

OR

[Name of the investigation] must be performed when:

  • The patient presents with [symptom/sign 1], [symptom/sign 2], and [symptom/sign 3].
  • A [name of test] is positive for [sign 1], [sign 2], and [sign 3] in the patient.

OR

[Name of the investigation] is the gold standard test for the diagnosis of [disease name].

OR

The diagnostic study of choice for [disease name] is [name of the investigation].

OR

There is no single diagnostic study of choice for the diagnosis of [disease name].

OR

There is no single diagnostic study of choice for the diagnosis of [disease name], but [disease name] can be diagnosed based on [name of the investigation 1] and [name of the investigation 2].

OR

[Disease name] is primarily diagnosed based on the clinical presentation.

OR

Investigations:

  • Among the patients who present with clinical signs of [disease name], the [investigation name] is the most specific test for the diagnosis.
  • Among the patients who present with clinical signs of [disease name], the [investigation name] is the most sensitive test for diagnosis.
  • Among the patients who present with clinical signs of [disease name], the [investigation name] is the most efficient test for diagnosis.

The comparison of various diagnostic studies for [disease name]

Test Sensitivity Specificity
Test 1 ...% ...%
Test 2 ...% ...%

[Name of test with higher sensitivity and specificity] is the preferred investigation based on the sensitivity and specificity

Diagnostic results

The following finding(s) on performing [investigation name] is(are) confirmatory for [disease name]:

  • [Finding 1]
  • [Finding 2]
Sequence of Diagnostic Studies

The [name of investigation] must be performed when:

  • The patient presented with symptoms/signs 1, 2, and 3 as the first step of diagnosis.
  • A positive [test] is detected in the patient, to confirm the diagnosis.

OR

The various investigations must be performed in the following order:

  • [Initial investigation]
  • [2nd investigation]

Name of Diagnostic Criteria

The American Joint Committee on Cancer (AJCC) has designated staging by TNM classification to define small intestine cancer[1]:

Primary Tumor (T):

TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ
T1a Tumor invades lamina propria
T1b Tumor invades submucosa
T2 Tumor invades muscularis propria
T3 Tumor invades through the muscularis propria into the subserosa or into the non-peritonealized perimuscular tissue (mesentery or retroperitoneum) with extension ≤2 cm
T4 Tumor perforates the visceral peritoneum or directly invades other organs or structures (includes other loops of small intestine, mesentery, or retroperitoneum >2 cm, and abdominal wall by way of serosa; for duodenum only, invasion of pancreas or bile duct)

Regional Lymph Nodes (N)

  • NX- Regional lymph nodes cannot be assessed
  • N0- No regional lymph node metastasis
  • N1- Metastasis in 1–3 regional lymph nodes
  • N2- Metastases in ≥4 regional lymph nodes

Distant Metastasis (M)

  • M0- No distant metastasis
  • M1- Distant metastasis

AJCC Stage Groupings

Stage T N M
0 Tis N0 M0
I T1 N0 M0
II T2 N0 M0
IIA T3 N0 M0
IIB T4 N0 M0
IIIA Any T N1 M0
IIIB Any T N2 M0
IV Any T Any N M1

References

  1. "Stage Information for Small Intestine Cancer".

Template:WH Template:WS